Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Post-operative Nausea and Vomiting Market to Become Worth US$ 3,100 Mn by 2026, Says TMR

Transparency Market Research
Posted on: 05 Jul 18
Post-operative Nausea and Vomiting Market to Become Worth US$ 3,100 Mn by 2026, Says TMR

PR Newswire

ALBANY, New York, July 5, 2018

ALBANY, New York, July 5, 2018 /PRNewswire/ --

Transparency Market Research (TMR) has published a new report titled, "Post-operative Nausea and Vomiting (PONV) Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018 - 2026", in June 2018. According to the report, the global post-operative nausea and vomiting (PONV) market was valued at US$ 1,608.6 Mn in 2017 and is projected to expand at a CAGR of 8% from 2018 to 2026. Increase in patient population experiencing post-operative nausea and vomiting, rise in adoption rate of combination therapies as well as non-pharmacological treatment modes, surge in funding, and launch of newer therapies are expected to boost the growth of the post-operative nausea and vomiting (PONV) during the forecast period from 2018 to 2026. North America and Europe are projected to dominate the global PONV market in the near future, primarily due to rise in patient population, steps taken by governments to support the development of novel therapies, and extensive research undertaken for the development of low cost drugs in these regions.

     (Logo: )

Read Report Overview:

The global PONV market in Asia Pacific is anticipated to expand at a high CAGR from 2018 to 2026. This can be ascribed to large patient population, rise in chronic diseases requiring surgical intervention in countries such as China and Japan, and various initiatives undertaken by the government and non-profit organizations to promote awareness about the treatment of post-operative complications. The PONV market in Asia Pacific is expected to expand at a CAGR of 8.5% during the forecast period.

High Incidence Rate and Significant Demand for Combination Therapy to Drive Market 

Post-operative nausea & vomiting is one of the most common complications after general anesthesia, occurring in up to 80% patients. Despite impressive advances in the field of anesthesia, 25% to 30% of patients continue to experience PONV. Multiple factors, including the anesthetic agent delivered, are associated with the increased incidence of PONV. A study published by the National Center for Biotechnology Information stated that the incidence of PONV has been reported in 20% to 40% patients with postoperative opioids. However, the incidence rate can increase to nearly 80% in patients with multiple risk factors for PONV, if antiemetic prophylaxis is not appropriate.

Get PDF Brochure for Research Insights at

Demand for combination drugs is rising among different classes, with various mechanism of actions for use in patients with moderate to high risk for PONV. Large number of clinical practice organizations also advocate usage of prophylactic antiemetic combinations. PONV is caused by multiple factors, and therefore, demand for combination antiemetic therapy among patients is high. None of the available medicines is single-handedly effective in preventing PONV, more so in high-risk patients. This is because majority of these medicines act through blockade of one receptor. Hence, better prophylaxis can be achieved using a combination therapy owing to the multi-modal etiology of PONV.

Serotonin Antagonists to be an Attractive Product Segment 

The report offers detailed segmentation of the global PONV market based on treatment type and distribution channel. In terms of treatment type, the serotonin antagonists segment is poised to expand at the highest CAGR during the forecast period from 2018 to 2026. Serotonin antagonists have a proven safety profile and are effective in the management of post-operative nausea and vomiting. Serotonin antagonists such as dolasetron, ondansetron, tropisetron, and granisetron competitively and selectively bind to 5-HT (3) receptors, thereby blocking serotonin binding in the regions of CNS involved in emesis.

Request a Custom Report at

Non-pharmacological Treatment Segment to Record High CAGR 

The non-pharmacological treatment segment is projected to dominate the global PONV market during the forecast period. The segment is anticipated to expand at a CAGR of 12% from 2018 to 2026. Significant rise in demand for non-pharmacological treatment methods has led to increase in usage of these methods. Surge in usage of non-pharmacologic treatment methods such as acupuncture, transcutaneous nerve stimulation, aromatherapy, and acupoint stimulation is likely to boost the growth of the segment during the forecast period.

Asia Pacific to Present Significant Opportunities 

In terms of revenue, the PONV market in Asia Pacific is expected to expand at a high CAGR during the forecast period from 2018 to 2026. The region is projected to gain market share by 2026. Asia Pacific's dominance of the global market can be attributed to rise in the number of patients undergoing surgical procedures and increase in compliance to pharmacologic and non-pharmacologic treatments. Presence of local pharmaceutical companies with massive manufacturing units in the countries of this region is expected to propel the market of this region.

Request a Sample of Post-operative Nausea and Vomiting Market:

M&A and New Product Development are Key Trends among Leading Players 

The report also provides profiles of the leading players operating in the global PONV market. Acacia Pharma, F. Hoffmann-La Roche AG, Novartis AG, Ani Pharmaceuticals, Inc., Camurus AB, Sanofi, Helsinn Holding S.A., Eisai Corporation, Merck & Co., and GlaxoSmithKline Corporation are the prominent players in the market having proprietary products and technologies. The major growth strategy adopted by these companies is new product development.

Popular Research Reports by TMR: 

About Us 

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company's exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR's data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.


Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

Research Blog:

SOURCE Transparency Market Research

PR Newswire

Last updated on: 05/07/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.